Press Release Feb 09 2024
Filed with NSE · · 2 pages · English
Summary by 6ix AI
Zydus Lifesciences Limited has issued a press release announcing that it received tentative approval from the USFDA for Dexamethasone Tablets USP, one milligram. The approval allows Zydus to manufacture and market the medication, which is used for various medical conditions. The product will be produced at the company's facility in Baddi, Himachal Pradesh. This marks a significant addition to Zydus's portfolio, which now includes numerous approvals from the USFDA.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Zydus Lifesciences Limited on 6ix
In the deck
Earlier from Zydus Lifesciences
- Press Release Feb 08 2024
- Press Release Jan 30 2024
- Press Release Jan 25 2024
- Press Release Jan 19 2024
- Press Release Jan 17 2024
Later from Zydus Lifesciences
- Press Release Feb 16 2024
- Zydus Lifesciences Limited Press Release Feb 26 2024
- Press Release Mar 13 2024
- Press Release Mar 14 2024
- Press Release Mar 16 2024
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences